Estimating measures of interaction on an additive scale for preventive exposures

Archive ouverte

Knol, Mirjam J. | Vanderweele, Tyler J. | Groenwold, Rolf H. H. | Klungel, Olaf H. | Rovers, Maroeska M. | Grobbee, Diederick E.

Edité par CCSD ; Springer Verlag -

International audience. Measures of interaction on an additive scale (relative excess risk due to interaction [RERI], attributable proportion [AP], synergy index [S]), were developed for risk factors rather than preventive factors. It has been suggested that preventive factors should be recoded to risk factors before calculating these measures. We aimed to show that these measures are problematic with preventive factors prior to recoding, and to clarify the recoding method to be used to circumvent these problems. Recoding of preventive factors should be done such that the stratum with the lowest risk becomes the reference category when both factors are considered jointly (rather than one at a time). We used data from a case-control study on the interaction between ACE inhibitors and the ACE gene on incident diabetes. Use of ACE inhibitors was a preventive factor and DD ACE genotype was a risk factor. Before recoding, the RERI, AP and S showed inconsistent results (RERI = 0.26 [95%CI: −0.30; 0.82], AP = 0.30 [95%CI: −0.28; 0.88], S = 0.35 [95%CI: 0.02; 7.38]), with the first two measures suggesting positive interaction and the third negative interaction. After recoding the use of ACE inhibitors, they showed consistent results (RERI = −0.37 [95%CI: −1.23; 0.49], AP = −0.29 [95%CI: −0.98; 0.40], S = 0.43 [95%CI: 0.07; 2.60]), all indicating negative interaction. Preventive factors should not be used to calculate measures of interaction on an additive scale without recoding.

Suggestions

Du même auteur

The (mis)use of overlap of confidence intervals to assess effect modification

Archive ouverte | Knol, Mirjam J. | CCSD

International audience

Impact of orlistat initiation on cardiovascular treatment use: a 6-year population-based cohort study

Archive ouverte | Czernichow, Sébastien | CCSD

International audience. Background: Trials of weight-loss drugs indicate some benefits on lipids, blood glucose, or blood pressure levels. Since obesity is associated with increased cardiovascular (CV) medication us...

PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study

Archive ouverte | Schmidt, Amand F. | CCSD

International audience. BACKGROUND: Statin treatment and variants in the gene encoding HMG-CoA reductase are associated with reductions in both the concentration of LDL cholesterol and the risk of coronary heart dis...

Chargement des enrichissements...